+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sofosbuvir"

Hepatitis C Treatment - Global Strategic Business Report - Product Thumbnail Image

Hepatitis C Treatment - Global Strategic Business Report

  • Report
  • April 2025
  • 208 Pages
  • Global
From
Hepatitis C Market Report 2025 - Product Thumbnail Image

Hepatitis C Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Hepatitis Drugs Market Report 2025 - Product Thumbnail Image

Hepatitis Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
From
From
  • 8 Results (Page 1 of 1)
Loading Indicator

Sofosbuvir is a prescription drug used to treat chronic hepatitis C virus (HCV) infection. It is a nucleotide analog inhibitor of the HCV NS5B polymerase, which is an enzyme that is essential for viral replication. Sofosbuvir is usually used in combination with other antiviral medications, such as ribavirin or peginterferon alfa, to treat HCV infection. It is also used to treat liver and kidney disorders, such as cirrhosis, chronic kidney disease, and end-stage renal disease. Sofosbuvir is a relatively new drug, having been approved by the U.S. Food and Drug Administration (FDA) in 2013. It is available in both generic and brand-name formulations. The brand-name formulation is marketed under the trade name Sovaldi. The market for sofosbuvir is highly competitive, with several major pharmaceutical companies offering the drug. These include Gilead Sciences, Mylan, Teva Pharmaceuticals, and Cipla. Show Less Read more